Myriad's Q1 Revenues Jump 20 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its first-quarter 2012 revenues increased 20 percent, as it beat Wall Street estimates on both the top and bottom line.

The Salt Lake City-based molecular diagnostics firm brought in total revenues of $110.5 million for the three months ended Sept. 30, up from $91.9 million for the first quarter of 2011. Analysts had expected revenues of $106.5 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.